Tolerability and usefulness of mercaptopurine in azathioprine-intolerant Japanese patients with ulcerative colitis

Digestive Endoscopy

Volumn 22, Issue 4, 2010, Pages 289-296

  Kuriyama, Motoaki ^a   Kato, Jun ^a   Suzuki, Hideyuki ^a   Akita, Mitsuhiro ^a   Hiraoka, Sakiko ^a   Okada, Hiroyuki ^a   Yamamoto, Kazuhide ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

adverse effects; azathioprine; mercaptopurine; tolerability; ulcerative colitis

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; PREDNISOLONE;

ABDOMINAL DISEASE; ADOLESCENT; ADULT; AGED; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CHILD; COLON RESECTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; INFECTION; JAPANESE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALAISE; MALE; PANCREATITIS; PARESTHESIA; PNEUMOCYSTIS PNEUMONIA; PROBABILITY; PRURITUS; RASH; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT OUTCOME; ULCERATIVE COLITIS;

6-MERCAPTOPURINE; ADOLESCENT; ADULT; AGED; AZATHIOPRINE; CHI-SQUARE DISTRIBUTION; COLITIS, ULCERATIVE; DRUG TOLERANCE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JAPAN; MALE; MIDDLE AGED; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 77957287589     PISSN: 09155635     EISSN: 14431661     Source Type: Journal    
DOI: 10.1111/j.1443-1661.2010.01009.x     Document Type: Article

References (27)

1. Adler DJ, Korelitz BI. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am. J. Gastroenterol. 1990 85 : 717 22.
2. Hawthorne AB, Logan RF, Hawkey CJ et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992 305 : 20 2.
3. Nielsen OH, Vainer B, Rask-Madsen J. Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment. Pharmacol. Ther. 2001 15 : 1699 708. (Pubitemid 33001133)
4. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002 50 : 485 9.
5. Lees CW, Maan AK, Hansoti B, Satsangi J, Arnott ID. Tolerability and safety of mercaptopurine in azathioprine intolerant patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 2008 27 : 220 7.
6. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993 34 : 1081 5.
7. Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998 115 : 813 21.
8. Hindorf U, Johansson M, Eriksson A, Kvifors E, Almer SH. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 2009 29 : 654 61.
9. Domènech E, Nos P, Papo M, López-San Román A, Garcia-Planella E, Gassull MA. 6-mercaptopurine in patients with inflammatory bowel disease and previous digestive intolerance of azathioprine. Scand. J. Gastroenterol. 2005 40 : 52 5.
10. Nagy F, Molnar T, Szepes Z, Farkas K, Nyari T, Lonovics J. Efficacy of 6-mercaptopurine treatment after azathioprine hypersensitivity in inflammatory bowel disease. World J. Gastroenterol. 2008 14 : 4342 6.
11. Bowen DG, Selby WS. Use of 6-mercaptopurine in patients with inflammatory bowel disease previously intolerant of azathioprine. Dig. Dis. Sci. 2000 45 : 1810 3.
12. Boulton-Jones JR, Pritchard K, Mahmoud AA. The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy. Aliment. Pharmacol. Ther. 2000 14 : 1561 5. (Pubitemid 32011729)
13. McGovern DP, Travis SP, Duley J, Shobowale-Bakre el M, Dalton HR. Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity. Gastroenterology 2002 122 : 838 9. (Pubitemid 34173838)
14. Hindorf U, Lindqvist M, Hildebrand H, Fagerberg U, Almer S. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 2006 24 : 331 42. (Pubitemid 43972901)
15. Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: Analysis of changes in disease activity over years. Gastroenterology 1994 107 : 3 11. (Pubitemid 24195339)
16. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N. Engl. J. Med. 1987 317 : 1625 9.
17. Eklund BI, Moberg M, Bergquist J, Mannervik B. Divergent activities of human glutathione transferases in the bioactivation of azathioprine. Mol. Pharmacol. 2006 70 : 747 54. (Pubitemid 44092335)
18. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum. Genet. 1980 32 : 651 62.
19. Derijks LJ, Gilissen LP, Engels LG et al. Pharmacokinetics of 6-thioguanine in patients with inflammatory bowel disease. Ther. Drug Monit. 2006 28 : 45 50. (Pubitemid 44391693)
20. Haglund S, Taipalensuu J, Peterson C, Almer S. IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations. Br. J. Clin. Pharmacol. 2008 65 : 69 77. (Pubitemid 350265173)
21. Andoh A, Tsujikawa T, Ban H et al. Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease. J. Gastroenterol. Hepatol. 2008 23 : 1373 7.
22. Colombel JF, Ferrari N, Debuysere H et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000 118 : 1025 30. (Pubitemid 30346978)
23. Gearry RB, Barclay ML, Burt MJ et al. Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 2003 18 : 395 400.
24. Ban H, Andoh A, Tanaka A et al. Analysis of thiopurine S-methyltransferase genotypes in Japanese patients with inflammatory bowel disease. Intern. Med. 2008 47 : 1645 8.
25. Gilissen LP, Derijks LJ, Bos LP, Bus PJ, Hooymans PM, Engels LG. Therapeutic drug monitoring in patients with inflammatory bowel disease and established azathioprine therapy. Clin. Drug Investig. 2004 24 : 479 86.
26. Goldenberg BA, Rawsthorne P, Bernstein CN. The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease. Am. J. Gastroenterol. 2004 99 : 1744 8. (Pubitemid 39237503)
27. Gearry RB, Barclay ML, Burt MJ, Collett JA, Chapman B. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol. Drug Saf. 2004 13 : 563 7. (Pubitemid 39214035)